Psoriasin overexpression confers drug resistance to cisplatin by activating ERK in gastric cancer

Li, Liting, Cui, Yuxin, Ye, Lin ORCID: https://orcid.org/0000-0002-0303-2409, Zhao, Zehang, Jiang, Wen ORCID: https://orcid.org/0000-0002-3283-1111 and Ji, Jiafu 2018. Psoriasin overexpression confers drug resistance to cisplatin by activating ERK in gastric cancer. International Journal of Oncology 53 (3) , pp. 1171-1182. 10.3892/ijo.2018.4455

Preview

PDF - Published Version Download (1MB) | Preview

Abstract

Psoriasin, a member of the S100 multigenic family, which is aberrantly expressed in a variety of human tumors, is considered as an attractive molecular target for cancer treatment. The present study aimed to characterize the role of psoriasin in gastric cancer (GC), the associated pathways through which it contributes to cancer development and progression, and the effect of psoriasin on cellular response to pre-operative chemotherapy in patients with GC. Expression of psoriasin mRNA and protein were analyzed using quantitative polymerase chain reaction and immunohistochemistry of gastric cancer cohorts, respectively. Gastric cancer cell models with differential expression of psoriasin were generated using stable cell lines that overexpressed psoriasin. The in vitro biological functions of the cells in response to psoriasin overexpression and to chemotherapeutic agents were assessed using various cell-based assays. Psoriasin was overexpressed in patients with advanced GC, and high psoriasin levels led to poor clinical outcomes. Increasing psoriasin expression in GC cell lines promoted cell proliferation, migration and invasion in vitro. Furthermore, psoriasin overexpression caused alterations in the levels of epithelial-mesenchymal transition-associated proteins, and activated the extracellular signal-regulated kinase signaling pathway. Additionally, higher levels of psoriasin expression were significantly associated a lack of response to neoadjuvant chemotherapy in patients with GC. Psoriasin overexpression tended to decrease the sensitivity of GC cells to cisplatin, potentially by inhibiting apoptosis or increasing the S-phase population. Taken together, these results indicate that psoriasin may be a promising therapeutic target for GC treatment, and a potential molecular marker to predict patient response to pre-operative chemotherapy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Spandidos Publications
ISSN:	1019-6439
Funders:	Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (grant no. ZYLX201701), China Scholarship Council, and Cardiff China Medical Research Collaborative and Cancer Research Wales
Date of First Compliant Deposit:	11 July 2018
Date of Acceptance:	7 June 2018
Last Modified:	07 May 2023 05:47
URI:	https://orca.cardiff.ac.uk/id/eprint/113011

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item